Afelimomab: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 16:22, 28 February 2020 editBoghog (talk \| contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 edits consistent citation formatting← Previous edit		Revision as of 15:01, 31 March 2020 edit undoFswitzer4 (talk \| contribs)Extended confirmed users10,578 editsm added FDA UNII to drug boxNext edit →
Line 27:		Line 27:
	\| CAS_number_Ref = {{cascite\|changed\|??}}		\| CAS_number_Ref = {{cascite\|changed\|??}}
	\| CAS_number = 156227-98-4		\| CAS_number = 156227-98-4
			\| UNII_Ref = {{fdacite\|correct\|FDA}}
			\| UNII = 6SC756X51V
	\| ATC_prefix = L04		\| ATC_prefix = L04
	\| ATC_suffix = AB03		\| ATC_suffix = AB03

Revision as of 15:01, 31 March 2020

Pharmaceutical compound

Afelimomab
Monoclonal antibody
Type	F(ab')₂ fragment
Source	Mouse
Target	TNFα
Clinical data
ATC code	L04AB03 (WHO)
Identifiers
CAS Number	156227-98-4
ChemSpider	none
UNII	6SC756X51V
KEGG	D07436
(what is this?) (verify)

Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.

References

Rondon E, Venkataraman R (August 2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care. 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.{{cite journal}}: CS1 maint: unflagged free DOI (link)
Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. (November 2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine. 32 (11): 2173–82. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628.

Immunosuppressive drugs / Immunosuppressants (L04)

Intracellular
(initiation)

Antimetabolites

purine synthesis inhibitors
- Azathioprine
- Mycophenolic acid

dihydroorotate dehydrogenase inhibitors
- Leflunomide
- Teriflunomide

antifolate
- Methotrexate

Macrolides/
other IL-2 inhibitors

FKBP/Cyclophilin/Calcineurin

IMiDs

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra
mTOR	Everolimus Ridaforolimus Sirolimus Temsirolimus Umirolimus Zotarolimus

Extracellular

Antibodies

Monoclonal

Serum target
(noncellular)

Complement component 5
- Eculizumab

TNF

Interleukin
- Anakinra
- Basiliximab
- Bimekizumab
- Briakinumab
- Brodalumab
- Canakinumab
- Daclizumab
- Guselkumab
- Ixekizumab
- Netakimab
- Olokizumab
- Rilonacept
- Risankizumab
- Sarilumab
- Satralizumab
- Secukinumab
- Siltuximab
- Sirukumab
- Spesolimab
- Tildrakizumab
- Tocilizumab
- Ustekinumab

Interleukin 5
- Mepolizumab

Immunoglobulin E
- Omalizumab

Interferon
- Faralimomab

IL-6
- Elsilimomab

IL-12, IL-13, and IL-23
- Lebrikizumab
- Ustekinumab

IL-17A
- Secukinumab

Cellular
target

IL-2 receptor/CD25

T-lymphocyte (Zolimomab aritox)

Unsorted

Polyclonal

-cept (Fusion)

CTLA-4
- Abatacept
- Belatacept
TNF inhibitor
- Etanercept
- Opinercept
Aflibercept
Alefacept
Rilonacept

Unsorted

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab Aselizumab Atezolizumab Benralizumab Camrelizumab Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Frexalimab Inebilizumab Itolizumab Lampalizumab Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140 Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab Lebrikizumab Olokizumab Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab Lemalesomab Sulesomab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: